One study showed that upregulated PD-L1 on tumor cells promotes mammalian target of rapamycin (mTOR) activity and glycolytic metabolism, which leads to tumor-mediated glucose restriction, alters CD8+ T-cell metabolism, and dampens the ability of T cells to produce IFN-γ. Here, IFNG is linked to neoplasm.